结直肠癌和结直肠腺瘤筛查方式的研究进展

doi:10.3969/j.issn.1674-8115.2022.05.017

摘要/Abstract

摘要：

近年来我国结直肠癌（colorectal cancer，CRC）发病率和死亡率呈上升趋势，严重威胁我国居民的生命健康，并造成了巨大的社会负担。筛查发现早期结直肠癌或腺瘤（癌前病变）可有效降低CRC发病率和死亡率。因此，在CRC的防治中，筛查的作用和意义重大。CRC和结直肠腺瘤的筛查技术包括以下4种类型。① 基于粪便的检查：粪便隐血试验（fecal occult based test，FOBT）、粪便DNA检测、粪便菌群标志物检测和粪便M2型丙酮酸激酶（M2 pruvate kinase，M2-PK）检测。② 影像学检查：计算机断层结肠成像（computed tomo-graphic colonography，CTC）、双对比钡灌肠（double-contrast barium enema，DCBE）和结肠胶囊内镜检查（colon capsule endoscopy，CCE）。③ 内窥镜检查：柔性乙状结肠镜（flexible sigmoidoscopy，FS）和结肠镜（colonoscopy，CS）。④ 液体活检：循环肿瘤细胞、循环肿瘤DNA（circulating tumor DNA，ctDNA）、循环肿瘤RNA（circulating tumor RNAs，ctRNAs）、蛋白质标志物、细胞外囊泡（extracellular vesicles，EVs）等。其中生物标志物DNA和RNA分子等可传达出丰富的人体健康状态信息，在筛查CRC中具有高敏感度和特异度，但在筛查腺瘤方面尚未广泛开展，需要对相关生物标志物开展更深入大规模的随机研究。该文对CRC和结直肠腺瘤筛查技术进行综述，介绍其原理、特点以及最新的研究进展，为CRC和结直肠腺瘤筛查技术在临床上的应用提供理论依据。

关键词: 结直肠癌, 结直肠腺瘤, 筛查

Abstract:

In recent years, the incidence and mortality of colorectal cancer (CRC) in China are on the rise, which seriously threatens the life and health of Chinese residents and causes a huge social burden. Screening to detect early colorectal cancer or adenoma (precancerous lesions) can effectively reduce the incidence and mortality of CRC. Therefore, the role and significance of screening in the prevention and treatment of CRC is significant. There are 4 types of screening techniques for CRC and colorectal adenoma. ① Stool-based tests: fecal occult based test (FOBT), fecal DNA test, fecal flora marker test, and fecal M2 pyruvate kinase (M2-PK) test. ② Imaging tests: computed tomo-graphic colonography (CTC), double-contrast barium enema (DCBE), and colon capsule endoscopy (CCE). ③ Endoscopy: flexible sigmoidoscopy (FS) and colonoscopy (CS). ④ Liquid biopsies: circulating tumor cells, circulating tumor DNA (ctDNA), circulating tumor RNAs (ctRNAs), protein markers, extracellular vesicles (EVs), etc. Among them, biomarkers DNA and RNA molecules can convey rich information about human health status and have high sensitivity and specificity in screening CRC, but they have not been widely carried out in screening adenomas, and more in-depth large-scale randomized studies of relevant biomarkers are needed. The review of CRC and colorectal adenoma screening technologies is present, introducing their principles, characteristics, and recent research advances to provide a theoretical basis for the clinical application of CRC and colorectal adenoma screening technologies.

Key words: colorectal cancer, colorectal adenoma, screening

中图分类号:

R735.3

赵敏, 褚以忞, 彭海霞. 结直肠癌和结直肠腺瘤筛查方式的研究进展[J]. 上海交通大学学报（医学版）, 2022, 42(5): 673-679.

ZHAO Min, CHU Yimin, PENG Haixia. Research advances in screening modalities for colorectal cancer and colorectal adenoma[J]. Journal of Shanghai Jiao Tong University (Medical Science), 2022, 42(5): 673-679.

参考文献 72

1	SUNG H, FERLAY J, SIEGEL R L, et al. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2021, 71(3): 209-249.
2	CAO W, CHEN H D, YU Y W, et al. Changing profiles of cancer burden worldwide and in China: a secondary analysis of the global cancer statistics 2020[J]. Chin Med J (Engl), 2021, 134(7): 783-791.
3	HANG D, JOSHI A D, HE X, et al. Colorectal cancer susceptibility variants and risk of conventional adenomas and serrated polyps: results from three cohort studies[J]. Int J Epidemiol, 2020, 49(1): 259-269.
4	BUCCAFUSCA G, PROSERPIO I, TRALONGO A C, et al. Early colorectal cancer: diagnosis, treatment and survivorship care[J]. Crit Rev Oncol Hematol, 2019, 136: 20-30.
5	MILETTE S, SICKLICK J K, LOWY A M, et al. Molecular pathways: targeting the microenvironment of liver metastases[J]. Clin Cancer Res, 2017, 23(21): 6390-6399.
6	国家消化系统疾病临床医学研究中心, 国家消化道早癌防治中心联盟, 中华医学会消化内镜学分会, 等. 中国早期结直肠癌筛查流程专家共识意见(2019,上海)[J]. 中华内科杂志, 2019, 58(10): 736-744.
	NATIONAL CLINICAL RESEARCH CENTER FOR DIGESTIVE DISEASES (SHANG HAI), NATIONAL EARLY GASTROINTESTINAL-CANCER PREVENTION & TREATMENT CENTER ALLIANCE (GECA), CHINESE SOCIETY OF DIGESTIVE ENDOSCOPY, et al. Chinese consensus of early colorectal cancer screening (2019, Shanghai) [J]. Chin J Intern Med, 2019, 58(10): 736-744.
7	CARROLL M R, SEAMAN H E, HALLORAN S P. Tests and investigations for colorectal cancer screening[J]. Clin Biochem, 2014, 47(10-11): 921-939.
8	ZAUBER A G, WINAWER S J, O'BRIEN M J, et al. Colonoscopic polypectomy and long-term prevention of colorectal-cancer deaths[J]. N Engl J Med, 2012, 366(8): 687-696.
9	BINEFA G, RODRÍGUEZ-MORANTA F, TEULE A, et al. Colorectal cancer: from prevention to personalized medicine[J]. World J Gastroenterol, 2014, 20(22): 6786-6808.
10	RABENECK L, RUMBLE R B, THOMPSON F, et al. Fecal immunochemical tests compared with guaiac fecal occult blood tests for population-based colorectal cancer screening[J]. Can J Gastroenterol, 2012, 26(3): 131-147.
11	LEE J K, LILES E G, BENT S, et al. Accuracy of fecal immunochemical tests for colorectal cancer: systematic review and meta-analysis[J]. Ann Intern Med, 2014, 160(3): 171.
12	SELBY K, LEVINE E H, DOAN C, et al. Effect of sex, age, and positivity threshold on fecal immunochemical test accuracy: a systematic review and meta-analysis[J]. Gastroenterology, 2019, 157(6): 1494-1505.
13	ROBERTSON D J, LEE J K, BOLAND C R, et al. Recommendations on fecal immunochemical testing to screen for colorectal neoplasia: a consensus statement by the US multi-society task force on colorectal cancer[J]. Gastroenterology, 2017, 152(5): 1217-1237.e1213.
14	YOUNG G P, RABENECK L, WINAWER S J. The global paradigm shift in screening for colorectal cancer[J]. Gastroenterology, 2019, 156(4): 843-851.e842.
15	HUANG Y, LI Q, GE W, et al. Predictive power of quantitative and qualitative fecal immunochemical tests for hemoglobin in population screening for colorectal neoplasm[J]. Eur J Cancer Prev, 2014, 23(1): 27-34.
16	IMPERIALE T F, GRUBER R N, STUMP T E, et al. Performance characteristics of fecal immunochemical tests for colorectal cancer and advanced adenomatous polyps: a systematic review and meta-analysis[J]. Ann Intern Med, 2019, 170(5): 319-329.
17	HAUG U, KNUDSEN A B, LANSDORP-VOGELAAR I, et al. Development of new non-invasive tests for colorectal cancer screening: the relevance of information on adenoma detection[J]. Int J Cancer, 2015, 136(12): 2864-2874.
18	IMPERIALE T F, KAHI C J. Cost-effectiveness of future biomarkers for colorectal cancer screening: quantified futility or call for innovation?[J]. Clin Gastroenterol Hepatol, 2018, 16(4): 483-485.
19	LANSDORP-VOGELAAR I, GOEDE S L, BOSCH L J W, et al. Cost-effectiveness of high-performance biomarker tests vs fecal immunochemical test for noninvasive colorectal cancer screening[J]. Clin Gastroenterol Hepatol, 2018, 16(4): 504-512.e511.
20	AHLQUIST D A, SKOLETSKY J E, BOYNTON K A, et al. Colorectal cancer screening by detection of altered human DNA in stool: feasibility of a multitarget assay panel[J]. Gastroenterology, 2000, 119(5): 1219-1227.
21	IMPERIALE T F, RANSOHOFF D F, ITZKOWITZ S H, et al. Multitarget stool DNA testing for colorectal-cancer screening[J]. N Engl J Med, 2014, 370(14): 1287-1297.
22	MU J, HUANG Y, CAI S, et al. Plausibility of an extensive use of stool DNA test for screening advanced colorectal neoplasia[J]. Clin Chim Acta, 2020, 501: 42-47.
23	PATEL S S, KILGORE M L. Cost effectiveness of colorectal cancer screening strategies[J]. Cancer Control, 2015, 22(2): 248-258.
24	WONG S H, KWONG T N Y, CHOW T C, et al. Quantitation of faecal Fusobacterium improves faecal immunochemical test in detecting advanced colorectal neoplasia[J]. Gut, 2017, 66(8): 1441-1448.
25	LIU K, YANG X, ZENG M, et al. The role of fecal Fusobacterium nucleatum and pks(+) Escherichia coli as early diagnostic markers of colorectal cancer[J]. Dis Markers, 2021, 2021: 1171239.
26	KIM Y C, KIM J H, CHEUNG D Y, et al. The usefulness of a novel screening kit for colorectal cancer using the immunochromatographic fecal tumor M2 pyruvate kinase test[J]. Gut Liver, 2015, 9(5): 641-648.
27	SPADA C, HASSAN C, BELLINI D, et al. Imaging alternatives to colonoscopy: CT colonography and colon capsule. European Society of Gastrointestinal Endoscopy (ESGE) and European Society of Gastrointestinal and Abdominal Radiology (ESGAR) Guideline-Update 2020[J]. Endoscopy, 2020, 52(12): 1127-1141.
28	MARTÍN-LÓPEZ J E, BELTRÁN-CALVO C, RODRÍGUEZ-LÓPEZ R, et al. Comparison of the accuracy of CT colonography and colonoscopy in the diagnosis of colorectal cancer[J]. Colorectal Dis, 2014, 16(3): O82-89.
29	LIN O S, KOZAREK R A, GLUCK M, et al. Preference for colonoscopy versus computerized tomographic colonography: a systematic review and meta-analysis of observational studies[J]. J Gen Intern Med, 2012, 27(10): 1349-1360.
30	KAWASAKI K, NAKAMURA S, EIZUKA M, et al. Is barium enema examination negligible for the management of colorectal cancer? Comparison with conventional colonoscopy and magnifying colonoscopy[J]. Jpn J Radiol, 2021, 39(12): 1159-1167.
31	LEE K L, CHIU N C, SU C W, et al. Less barium enema, more colonoscopy: a 12-year nationwide population-based study in Taiwan[J]. J Chin Med Assoc, 2019, 82(4): 312-317.
32	MAASER C, STURM A, VAVRICKA S R, et al. ECCO-ESGAR Guideline for Diagnostic Assessment in IBD Part 1: initial diagnosis, monitoring of known IBD, detection of complications[J]. J Crohns Colitis, 2019, 13(2): 144-164.
33	BALTES P, BOTA M, ALBERT J, et al. PillCamColon2 after incomplete colonoscopy - a prospective multicenter study[J]. World J Gastroenterol, 2018, 24(31): 3556-3566.
34	SPADA C, HASSAN C, BARBARO B, et al. Colon capsule versus CT colonography in patients with incomplete colonoscopy: a prospective, comparative trial[J]. Gut, 2015, 64(2): 272-281.
35	REX D K, ADLER S N, AISENBERG J, et al. Accuracy of capsule colonoscopy in detecting colorectal polyps in a screening population[J]. Gastroenterology, 2015, 148(5): 948-957.e942.
36	GROBBEE E J, VAN DER VLUGT M, VAN VUUREN A J, et al. Diagnostic yield of one-time colonoscopy vs one-time flexible sigmoidoscopy vs multiple rounds of mailed fecal immunohistochemical tests in colorectal cancer screening[J]. Clin Gastroenterol Hepatol, 2020, 18(3): 667-675.e661.
37	HOLME Ø, LØBERG M, KALAGER M, et al. Long-term effectiveness of sigmoidoscopy screening on colorectal cancer incidence and mortality in women and men: a randomized trial[J]. Ann Intern Med, 2018, 168(11): 775-782.
38	ATKIN W, WOOLDRAGE K, PARKIN D M, et al. Long term effects of once-only flexible sigmoidoscopy screening after 17 years of follow-up: the UK Flexible Sigmoidoscopy Screening randomised controlled trial[J]. Lancet, 2017, 389(10076): 1299-1311.
39	LI W, ZHANG L, HAO J, et al. Validity of APCS score as a risk prediction score for advanced colorectal neoplasia in Chinese asymptomatic subjects: a prospective colonoscopy study[J]. Medicine (Baltimore), 2016, 95(41): e5123.
40	BRENNER H, STOCK C, HOFFMEISTER M. Effect of screening sigmoidoscopy and screening colonoscopy on colorectal cancer incidence and mortality: systematic review and meta-analysis of randomised controlled trials and observational studies[J]. BMJ, 2014, 348: g2467.
41	SHARAF R N, LADABAUM U. Comparative effectiveness and cost-effectiveness of screening colonoscopy vs. sigmoidoscopy and alternative strategies[J]. Am J Gastroenterol, 2013, 108(1): 120-132.
42	HADJIPETROU A, ANYFANTAKIS D, GALANAKIS C G, et al. Colorectal cancer, screening and primary care: a mini literature review[J]. World J Gastroenterol, 2017, 23(33): 6049-6058.
43	KAMINSKI M F, ROBERTSON D J, SENORE C, et al. Optimizing the quality of colorectal cancer screening worldwide[J]. Gastroenterology, 2020, 158(2): 404-417.
44	YAMADA T, MATSUDA A, KOIZUMI M, et al. Liquid biopsy for the management of patients with colorectal cancer[J]. Digestion, 2019, 99(1): 39-45.
45	NORMANNO N, CERVANTES A, CIARDIELLO F, et al. The liquid biopsy in the management of colorectal cancer patients: current applications and future scenarios[J]. Cancer Treat Rev, 2018, 70: 1-8.
46	SYMONDS E L, COCK C, MENG R, et al. Uptake of a colorectal cancer screening blood test in people with elevated risk for cancer who cannot or will not complete a faecal occult blood test[J]. Eur J Cancer Prev, 2018, 27(5): 425-432.
47	GRILLET F, BAYET E, VILLERONCE O, et al. Circulating tumour cells from patients with colorectal cancer have cancer stem cell hallmarks in ex vivo culture[J]. Gut, 2017, 66(10): 1802-1810.
48	TSAI W S, YOU J F, HUNG H Y, et al. Novel circulating tumor cell assay for detection of colorectal adenomas and cancer[J]. Clin Transl Gastroenterol, 2019, 10(10): e00088.
49	SCHWARZENBACH H, HOON D S, PANTEL K. Cell-free nucleic acids as biomarkers in cancer patients[J]. Nat Rev Cancer, 2011, 11(6): 426-437.
50	KHAKOO S, GEORGIOU A, GERLINGER M, et al. Circulating tumour DNA, a promising biomarker for the management of colorectal cancer[J]. Crit Rev Oncol Hematol, 2018, 122: 72-82.
51	SPINDLER K L, PALLISGAARD N, ANDERSEN R F, et al. Circulating free DNA as biomarker and source for mutation detection in metastatic colorectal cancer[J]. PLoS One, 2015, 10(4): e0108247.
52	DING Y, LI W, WANG K, et al. Perspectives of the application of liquid biopsy in colorectal cancer[J]. Biomed Res Int, 2020, 2020: 6843180.
53	REINERT T, SCHØLER L V, THOMSEN R, et al. Analysis of circulating tumour DNA to monitor disease burden following colorectal cancer surgery[J]. Gut, 2016, 65(4): 625-634.
54	BETTEGOWDA C, SAUSEN M, LEARY R J, et al. Detection of circulating tumor DNA in early- and late-stage human malignancies[J]. Sci Transl Med, 2014, 6(224): 224ra224.
55	LUO H, ZHAO Q, WEI W, et al. Circulating tumor DNA methylation profiles enable early diagnosis, prognosis prediction, and screening for colorectal cancer[J]. Sci Transl Med, 2020, 12(524): eaax7533.
56	MARCUELLO M, VYMETALKOVA V, NEVES R P L, et al. Circulating biomarkers for early detection and clinical management of colorectal cancer[J]. Mol Aspects Med, 2019, 69: 107-122.
57	SONG L, JIA J, PENG X, et al. The performance of the SEPT9 gene methylation assay and a comparison with other CRC screening tests: a meta-analysis[J]. Sci Rep, 2017, 7(1): 3032.
58	HU J, HU B, GUI Y C, et al. Diagnostic value and clinical significance of methylated SEPT9 for colorectal cancer: a meta-analysis[J]. Med Sci Monit, 2019, 25: 5813-5822.
59	HE N, SONG L, KANG Q, et al. The pathological features of colorectal cancer determine the detection performance on blood ctDNA[J]. Technol Cancer Res Treat, 2018, 17: 1533033818791794.
60	FERNÁNDEZ-LÁZARO D, GARCÍA HERNÁNDEZ J L, GARCÍA A C, et al. Liquid biopsy as novel tool in precision medicine: origins, properties, identification and clinical perspective of cancer's biomarkers[J]. Diagnostics (Basel), 2020, 10(4): 215.
61	MELTZER P S. Cancer genomics: small RNAs with big impacts[J]. Nature, 2005, 435(7043): 745-746.
62	ZUO Z, JIANG Y, ZENG S, et al. The value of microRNAs as the novel biomarkers for colorectal cancer diagnosis: a meta-analysis[J]. Pathol Res Pract, 2020, 216(10): 153130.
63	YAN L, ZHAO W, YU H, et al. A comprehensive meta-analysis of microRNAs for predicting colorectal cancer[J]. Medicine (Baltimore), 2016, 95(9): e2738.
64	JELSKI W, MROCZKO B. Biochemical markers of colorectal cancer-present and future[J]. Cancer Manag Res, 2020, 12: 4789-4797.
65	ALVES MARTINS B A, DE BULHÕES G F, CAVALCANTI I N, et al. Biomarkers in colorectal cancer: the role of translational proteomics research[J]. Front Oncol, 2019, 9: 1284.
66	GONZALEZ-PONS M, CRUZ-CORREA M. Colorectal cancer biomarkers: where are we now?[J]. Biomed Res Int, 2015, 2015: 149014.
67	BAQAR A R, WILKINS S, STAPLES M, et al. The role of preoperative CEA in the management of colorectal cancer: a cohort study from two cancer centres[J]. Int J Surg, 2019, 64: 10-15.
68	KOULIS C, YAP R, ENGEL R, et al. Personalized medicine-current and emerging predictive and prognostic biomarkers in colorectal cancer[J]. Cancers (Basel), 2020, 12(4): 812.
69	BHARDWAJ M, WEIGL K, TIKK K, et al. Multiplex screening of 275 plasma protein biomarkers to identify a signature for early detection of colorectal cancer[J]. Mol Oncol, 2020, 14(1): 8-21.
70	DESMOND B J, DENNETT E R, DANIELSON K M. Circulating extracellular vesicle microrna as diagnostic biomarkers in early colorectal cancer-a review[J]. Cancers (Basel), 2019, 12(1): 52.
71	MOUSAVI S, MOALLEM R, HASSANIAN S M, et al. Tumor-derived exosomes: potential biomarkers and therapeutic target in the treatment of colorectal cancer[J]. J Cell Physiol, 2019, 234(8): 12422-12432.
72	YAN S, HAN B, GAO S, et al. Exosome-encapsulated microRNAs as circulating biomarkers for colorectal cancer[J]. Oncotarget, 2017, 8(36): 60149-60158.

[1]	龚其雨, 陈磊. 多组学数据解析循环及浸润性B细胞在结直肠癌免疫微环境中的作用[J]. 上海交通大学学报（医学版）, 2022, 42(4): 472-481.
[2]	徐莹, 褚以忞, 杨大明, 李吉, 张海芹, 彭海霞. 基于差异表达基因组合构建高度微卫星不稳定结直肠癌转移预测模型[J]. 上海交通大学学报(医学版), 2021, 41(9): 1197-1206.
[3]	钱珠萍, 杨艳. 肝硬化并发轻微型肝性脑病的筛查模型建立与评价[J]. 上海交通大学学报(医学版), 2021, 41(9): 1228-1232.
[4]	傅文霞, 陈力秀, 乐佳玮, 李若谷. 穿戴式动态心电图记录仪在心房颤动筛查中的应用[J]. 上海交通大学学报(医学版), 2021, 41(7): 926-930.
[5]	程盛, 赵益, 王永琛, 黄平. BRAF基因突变对肝切除后的结直肠癌肝转移患者预后影响的meta分析[J]. 上海交通大学学报(医学版), 2021, 41(6): 786-792.
[6]	包汝娟, 陈慧芳, 董宇, 叶幼琼, 苏冰. 基于转录组异常表达构建结直肠癌特征基因预后风险评分模型[J]. 上海交通大学学报(医学版), 2021, 41(3): 285-296.
[7]	马燕如, 季林华, 童天颖, 严宇青, 沈超琴, 张昕雨, 曹颖颖, 洪洁, 陈豪燕. 基于单细胞RNA测序的结直肠癌预后预测模型的建立和验证[J]. 上海交通大学学报(医学版), 2021, 41(2): 159-165.
[8]	傅中懋, 罗再, 戎泽印, 章建明, 李腾飞, 余志龙, 黄陈. 基于高通量测序的结直肠癌组织中环状RNA功能研究与预后分析[J]. 上海交通大学学报(医学版), 2021, 41(2): 187-195.
[9]	徐文晖, 卞京, 郑磊贞. 结直肠癌和高脂饮食关系的研究进展及其防治对策[J]. 上海交通大学学报(医学版), 2021, 41(11): 1514-1517.
[10]	陈智灵, 罗晨, 赵康佳, 沈玲, 胡三莲. 2种镇痛方式在结直肠癌术后应用效果的meta分析[J]. 上海交通大学学报(医学版), 2021, 41(10): 1344-1350.
[11]	严宇青，沈超琴，陈豪燕，洪洁#，王震华#. lnc-MTBP-5在结直肠癌中的表达及其对细胞侵袭能力的影响[J]. 上海交通大学学报(医学版), 2020, 40(9): 1193-1201.
[12]	苏杭，马晓静，应令雯，贺星星，朱玮，唐峻岭，王煜非，包玉倩，周健. 1,5-脱水葡萄糖醇或糖化白蛋白联合空腹血糖筛查糖尿病的效率比较[J]. 上海交通大学学报（医学版）, 2019, 39(9): 1077-.
[13]	张昕恬，陈锦南，王奇雯，李晓波. 程序性细胞死亡蛋白 1配体 2在激光共聚焦显微内镜诊断结直肠癌中应用的初步探索[J]. 上海交通大学学报（医学版）, 2019, 39(8): 881-.
[14]	贾芷莹 1, 2，董旻晔 1, 2，施贞夙 2, 3，金春林 4，李国红 1, 2. 基于机器学习的轻度认知功能障碍筛查研究[J]. 上海交通大学学报（医学版）, 2019, 39(8): 908-.
[15]	孙伟杰 1，徐莹 1，杨静 2，褚以忞 1，杨大明 1，李吉 1，彭海霞 1. 散发性结直肠癌 DNA错配修复系统蛋白表达及其临床意义[J]. 上海交通大学学报（医学版）, 2019, 39(7): 759-.